SCLX Scilex Holding Company
Legal ·
The Federal Circuit affirmed on Aug. 4, 2026 that Aveva's generic does not infringe Scilex's ZTlido patents. Defendants were Aveva Drug Delivery Systems, Apotex Corp. and Apotex, Inc.
Mevi et al. v. Ji et al. names Scilex, Semnur and others not listed in the 10-Q. The court stayed the case on June 25, 2026; Scilex's filings do not identify the other defendants.
Scilex Holding Company says it needs more time to finish its first-quarter 2026 financial statements, including the consolidation of Vivasor Holding Company, and expects to file by May 20, 2026. Its 2025 annual report carries a going-concern warning and an accumulated deficit of about $921.8 million.
Scilex Holding Company says it could not file its annual report by the March 31, 2026 due date and expects to file by April 15, 2026. It says it needs more time to finalize financial statements, including consolidating Vivasor Holding Company.
Scilex met the $1.00 minimum closing bid price requirement on April 30, 2025. Its common stock and public warrants stay on the Nasdaq Capital Market.
Semnur signed Amendment No. 1 on April 16, 2025, covering Denali's move from Nasdaq to OTC quotation and extending its deadlines.
Oramed and the Tranche B holders waived the missed quarterly filing on November 21, 2024. Scilex must deliver its September 2024 financial statements by January 20, 2025, through a new independent auditor.
The company missed the November 14, 2024 due date for its report on the quarter ended September 30, 2024. The notice warns that an ongoing review may identify errors or control deficiencies in its accounting practices.
Scilex Holding Company is a revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for acute and chronic pain. Its three commercial products are ZTlido, a prescription lidocaine topical system for neuropathic pain from postherpetic neuralgia; ELYXYB, a ready-to-use oral celecoxib solution for acute migraine in adults; and GLOPERBA, a liquid oral colchicine for prophylaxis of painful gout flares in adults. ZTlido is manufactured in Japan by Oishi Koseido Co., Ltd., and the company relies on Oishi and Itochu Chemical Frontier Corporation for it. GLOPERBA rights come from a license with RxOmeg Therapeutics LLC, also called Romeg. Its candidates include SP-102 (SEMDEXA), a viscous gel corticosteroid for epidural injection in sciatica; SP-103, a triple-strength lidocaine topical system for acute low back pain; and SP-104, a low-dose delayed-release naltrexone for fibromyalgia. The text also describes a cryptocurrency treasury strategy under which the company intends to invest in bitcoin, Ethereum and other blockchain-linked cryptocurrencies.
| Product or program | What it is | Stage |
|---|---|---|
| ZTlido | Prescription lidocaine topical system for postherpetic neuralgia pain | FDA-approved; commercial product |
| ELYXYB | Ready-to-use oral celecoxib solution for acute migraine in adults | FDA-approved; commercial product |
| GLOPERBA | Liquid oral colchicine for prophylaxis of painful gout flares in adults | FDA-approved; launched June 2024 |
| SP-102 (SEMDEXA) | Viscous gel corticosteroid for epidural injection to treat sciatica | Phase 3 study completed |
| SP-103 | Triple-strength lidocaine topical system for acute low back pain | Phase 2 trial completed |
| SP-104 | Low-dose delayed-release naltrexone for fibromyalgia | Phase 1 trials completed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $30.3 million | $56.6 million |
| Research and development | $20.7 million | $9.6 million |
| Net income (loss) | -$374.1 million | -$72.8 million |
| Cash from operations | $3.8 million | $19.3 million |
| Cash and equivalents | $5.0 million | $3.3 million |
Our latest story on this, dated May 15, 2026: "Scilex files NT 10-Q late filing notice, expects first quarter 10-Q by May 20, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 21, 2025: "Scilex unit Semnur amends Denali merger deal, moves outside date to September 30, 2025". The story links the filing or release it is based on. Read the story.
Scilex Holding Company trades under the ticker SCLX on NASDAQ.
Scilex Holding Company is listed on NASDAQ.
The SEC Central Index Key (CIK) for Scilex Holding Company is 1820190. Its filings are on SEC EDGAR.
8,493,000 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Scilex Holding Company under United States.
Our directory classifies Scilex Holding Company as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Scilex Holding Company is US80880W2052.
aibio.space lists Scilex Holding Company among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Scilex Holding Company is a revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for acute and chronic pain. Its three commercial products are ZTlido, a prescription lidocaine topical system for neuropathic pain from postherpetic neuralgia; ELYXYB, a ready-to-use oral celecoxib solution for acute migraine in adults; and GLOPERBA, a liquid oral colchicine for prophylaxis of painful gout flares in adults.
ZTlido: Prescription lidocaine topical system for postherpetic neuralgia pain Stage: FDA-approved; commercial product.
ELYXYB: Ready-to-use oral celecoxib solution for acute migraine in adults Stage: FDA-approved; commercial product.
$30.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,7.01,8.01,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio